Related Experiment Video
Updated: May 14, 2026

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
HDAC3 regulates stability of estrogen receptor α mRNA
Shohei Oie1, Kazuya Matsuzaki, Wataru Yokoyama
1Graduate School of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8577, Japan.
Abstract:
Estrogen receptor alpha (ERα) expression is a risk factor for breast cancer. HDAC inhibitors have been demonstrated to down-regulate ERα expression in ERα-positive breast cancer cell lines, but the molecular mechanisms are poorly understood. Here, we showed that HDAC inhibitors decrease the stability of ERα mRNA, and that knockdown of HDAC3 decreases the stability of ERα mRNA and suppresses estrogen-dependent proliferation of ERα-positive MCF-7 breast cancer cells. In the Oncomine database, expression levels of HDAC3 in ERα-positive tumors are higher than those in ERα-negative tumors, thus suggesting that HDAC3 is necessary for ERα mRNA stability, and is involved in the estrogen-dependent proliferation of ERα-positive tumors.
Insights
Histone deacetylase 3 (HDAC3) stabilizes estrogen receptor alpha (ERα) mRNA, promoting ERα-positive breast cancer proliferation. Inhibiting HDAC3 may offer a therapeutic strategy for ERα-positive breast cancers.
Area of Science:
- Molecular biology
- Oncology
- Biochemistry
Background:
- Estrogen receptor alpha (ERα) expression is a known risk factor for breast cancer development.
- Histone deacetylase (HDAC) inhibitors show potential in down-regulating ERα expression in ERα-positive breast cancer cell lines.
- The precise molecular mechanisms underlying HDAC inhibitor effects on ERα expression remain unclear.
Purpose of the Study:
- To elucidate the molecular mechanisms by which HDAC inhibitors affect ERα expression.
- To investigate the role of HDAC3 in ERα mRNA stability and breast cancer cell proliferation.
- To explore the potential of targeting HDAC3 for ERα-positive breast cancer therapy.
Main Methods:
- Utilized breast cancer cell lines (MCF-7) to study ERα mRNA stability.
- Employed knockdown techniques to deplete HDAC3 expression.
- Analyzed HDAC3 expression levels in ERα-positive versus ERα-negative tumors using the Oncomine database.
Main Results:
- HDAC inhibitors were found to decrease the stability of ERα mRNA.
- Knockdown of HDAC3 led to decreased ERα mRNA stability and suppressed estrogen-dependent proliferation in MCF-7 cells.
- HDAC3 expression levels were significantly higher in ERα-positive tumors compared to ERα-negative tumors.
Conclusions:
- HDAC3 is crucial for maintaining ERα mRNA stability.
- HDAC3 plays a significant role in the estrogen-dependent proliferation of ERα-positive breast cancer cells.
- Targeting HDAC3 presents a potential therapeutic avenue for ERα-positive breast cancers.
Related Concept Videos
RNA Stability
RNA Stability
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Co-activators and Co-repressors

